BioSpace News Archive

Catabasis Pharmaceuticals, Inc. announced the appointment of Gregg Lapointe to its Board of Directors

Data expected from the PEN-221 Phase 2a trial and PEN-866 Phase 1 dose escalation and safety trial in 2019

Showcase Held During J.P. Morgan Healthcare Conference in San Francisco

The global von Willebrand disease treatment market 2019-2023 is expected to post a CAGR of close to 7% during the forecast period, according to the latest market research report by Technavio

Bolstering Its Presence in Lake County, Illinois

Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that, under the terms of a reorganization and share exchange agreement approved by the Board of Directors, it has acquired from Bay City Capital (BCC) the remaining 20% equity share of its device subsidiary, ThermoGenesis Corp.

Selexis SA announced its planned participation at several industry conferences during the first quarter of 2019